"Despite the rhetoric at times, there’s a huge appetite in healthcare for digital technology to act as an adjacent technology to traditional approaches."
In Conversation
"One of NICE’s hallmarks is that that we have always been prepared to explain our reasoning and evaluation process to patients, companies and the public, usually…
"Although the UK is a fantastic place to do business, the NHS’ slow uptake of new products can be frustrating for the pharmaceutical industry."
On the positive side, UK-based biotech companies are raising considerable venture capital and two or three international companies have recently announced they are making new investments…
"It's important to recognize that generic competition does not only reduce cost and increase patient access to medicines, it spurs innovation."
One of the key matters for us is that we don’t have direct customers. We ask people to give us money and essentially, we give that…
In the UK, when people want to help those affected by diseases like Alzheimer’s, they often go to charities rather than the State
In an exclusive interview at the eyeforpharma Barcelona Summit 2016, Janssen EMEA's Jane Griffiths speaks out about patient-centricity, sustainability and the dawning of a new world of healthcare.
In an exclusive interview at the eyeforpharma Barcelona Summit 2016, GSK's Danie Du Plessis speaks out about patient-centricity and the growing role of medical affairs in the…
Can you provide us with an overview of what the UK market represents for the greater Lonza group? Lonza Biologics is a contract manufacturing organisation employing…
Having worked in the pharmaceutical industry for the past three decades, what attracted you to Martindale Pharma in October 2010 and what plans do you have…
As the head of Eisai’s European operations, how would you assess the relevance of the European market for Eisai’s global operations when compared to the US…
